Disease course and disability outcomes in MOG-antibody disease in the UK

Disease course and disability outcomes in MOG-antibody disease in the UK

Bibliographic Details
Main Authors:	Jurynczyk, M, Messina, S, Woodhall, M, Raza, N, Everett, R, Roca-Fernandez, A, Tackley, G, Hamid, S, Sheard, A, Reynolds, G, Chandratre, S, Hemingway, C, Jacob, A, Vincent, A, Leite, M, Waters, P, Palace, J
Format:	Conference item
Published:	SAGE Publications 2017

Similar Items

Clinical presentation and prognosis in MOG-antibody disease: a UK study
by: Jurynczyk, M, et al.
Published: (2017)

Distinguishing the brain MRI features of MS, AQP4-and MOG-antibody disease.
by: Jurynczyk, M, et al.
Published: (2016)

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
by: Waters, P, et al.
Published: (2015)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
by: Jurynczyk, M, et al.
Published: (2017)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
by: Jurynczyk, M, et al.
Published: (2017)

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
by: Juryńczyk, M, et al.
Published: (2016)

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
by: Waters, P, et al.
Published: (2015)

No strong HLA association with MOG antibody disease in the UK population
by: Grant-Peters, M, et al.
Published: (2021)

Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis
by: Jurynczyk, M, et al.
Published: (2017)

International multicenter examination of MOG antibody assays
by: Reindl, M, et al.
Published: (2020)

Frequency of MOG-IgG in cerebrospinal fluid versus serum
by: Pace, S, et al.
Published: (2021)

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies
by: Yeo, T, et al.
Published: (2020)

Recurrent optic neuritis associated with MOG antibody seropositivity
by: Chang, T, et al.
Published: (2017)

We need to talk about MOG
by: Waters, P, et al.
Published: (2020)

The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis
by: Messina, S, et al.
Published: (2021)

RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES
by: Elsone, L, et al.
Published: (2014)

A 41-year-old woman with acute weakness and encephalopathy associated with MOG antibodies.
by: Morris, K, et al.
Published: (2015)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
by: Tackley, G, et al.
Published: (2016)

Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
by: Piccolo, L, et al.
Published: (2016)

Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis
by: Hyun, J, et al.
Published: (2018)

A multicenter comparison of MOG-IgG cell-based assays
by: Waters, P, et al.
Published: (2019)

Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis
by: Tackley, G, et al.
Published: (2016)

Epilepsy in patients with MOG antibody disease
by: Varvara E. Avdeeva, et al.
Published: (2021-10-01)

MOG-IGG IN NMO AND NMO-LIKE DISORDERS
by: Luppe, S, et al.
Published: (2014)

An international multicentre validation experiment for MOG antibodies
by: Reindl, M, et al.
Published: (2018)

Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases
by: Kim, Y, et al.
Published: (2020)

Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients
by: Whittam, DH, et al.
Published: (2020)

Overlapping CNS inflammatory diseases: differentiating features of NMO and MS.
by: Juryńczyk, M, et al.
Published: (2015)

Understanding MOG antibody-associated disease in Brazil
by: Dagoberto Callegaro, et al.
Published: (2023-11-01)

MOG-IgG1 antibodies in children
by: Waters, P, et al.
Published: (2018)

Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder
by: Hacohen, Y, et al.
Published: (2018)

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
by: Kitley, J, et al.
Published: (2014)

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study
by: Kitley, J, et al.
Published: (2014)

Humoral signatures of MOG-antibody-associated disease track with age and disease activity
by: Spatola, Marianna, et al.
Published: (2023)

Prospective clinical and MRI characterization of children with serum anti-MOG antibodies meeting the multiple sclerosis diagnostic criteria
by: Fadda, G, et al.
Published: (2018)

Myelin-oligodendrocyte glycoprotein antibody-mediated acute inflammatory demyelinating disease mimicking neuromyelitis optica
by: Kitley, J, et al.
Published: (2011)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
by: Yeo, T, et al.
Published: (2019)

Peripherally derived macrophages as major phagocytes in MOG encephalomyelitis
by: Kwon, Y, et al.
Published: (2019)

Peripheral nervous system manifestations of MOG antibody associated disease
by: Pranjal Gupta, et al.
Published: (2024-04-01)

Investigating the association between neoplasms and MOG antibody-associated disease
by: Milena Trentinaglia, et al.
Published: (2023-06-01)